Enarodustat (development code JTZ-951; brand name Enaroy) is a drug used for the treatment of anemia, especially when associated with

chronic kidney disease Chronic kidney disease (CKD) is a type of kidney disease in which a gradual loss of kidney function occurs over a period of months to years. Initially generally no symptoms are seen, but later symptoms may include leg swelling, feeling tired, vo ...

(CKD). Enarodustat functions as a inhibitor of hypoxia inducible factor-proly hydroxylase (HIF-PH). The drug was approved in September 2020 in Japan for anemia associated with CKD and is currently in

clinical development Drug development is the process of bringing a new pharmaceutical drug to the market once a lead compound has been identified through the process of drug discovery. It includes preclinical research on microorganisms and animals, filing for regu ...

in the United States and South Korea. The drug is being developed by Japan Tobacco and JW Pharmaceutical.

References

Drugs acting on the blood and blood forming organs Alpha-Amino acids Triazolopyridines Secondary amino acids {{blood-drug-stub